Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 3
1990 1
1991 2
1992 7
1993 10
1994 12
1995 10
1996 12
1997 27
1998 67
1999 110
2000 128
2001 164
2002 207
2003 316
2004 419
2005 493
2006 638
2007 653
2008 795
2009 1011
2010 1151
2011 1181
2012 1148
2013 1211
2014 1080
2015 1015
2016 1041
2017 947
2018 906
2019 930
2020 966
2021 905
2022 857
2023 817
2024 259

Text availability

Article attribute

Article type

Publication date

Search Results

17,263 results

Results by year

Filters applied: . Clear all
Page 1
Clopidogrel Pharmacogenetics.
Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Pereira NL, et al. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811. Circ Cardiovasc Interv. 2019. PMID: 30998396 Free PMC article. Review.
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel …
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional …
The Role of Clopidogrel in 2020: A Reappraisal.
Patti G, Micieli G, Cimminiello C, Bolognese L. Patti G, et al. Cardiovasc Ther. 2020 Mar 16;2020:8703627. doi: 10.1155/2020/8703627. eCollection 2020. Cardiovasc Ther. 2020. PMID: 32284734 Free PMC article. Review.
In patients with very high-risk TIA or stroke, short-term DAPT with clopidogrel plus aspirin for 21-28 days, followed by clopidogrel monotherapy for up to 90 days, is recommended. Clopidogrel monotherapy may also be used in patients with symptomatic PAD. ...
In patients with very high-risk TIA or stroke, short-term DAPT with clopidogrel plus aspirin for 21-28 days, followed by clopidogr …
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.
Chen J, Tang Y, Zhong Y, Wei B, Huang XR, Tang PM, Xu A, Lan HY. Chen J, et al. Mol Ther. 2022 Sep 7;30(9):3017-3033. doi: 10.1016/j.ymthe.2022.06.019. Epub 2022 Jul 5. Mol Ther. 2022. PMID: 35791881 Free PMC article.
Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, which we investigated by silencing P2Y12 or treating unilateral ureteral obstruction (UUO) in LysM-Cre/Rosa Tomato mice with clopidogrel …
Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, w …
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
Dickie JS, Scott LJ. Dickie JS, et al. Am J Cardiovasc Drugs. 2006;6(6):407-14. doi: 10.2165/00129784-200606060-00008. Am J Cardiovasc Drugs. 2006. PMID: 17192131 Review.
Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved for the reduction of atherothrombotic events in patients with ST-segment elevation myocardial infarction (STEMI). ...Clopidogrel trea …
Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of ADP-induced platelet aggregation, is approved …
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Ono K, Kadota K, Suwa S, Morishima I, Yoshida R, Hata Y, Akao M, Yagi M, Suematsu N, Morino Y, Yokomatsu T, Takamisawa I, Noda T, Doi M, Okayama H, Nakamura Y, Hibi K, Sakamoto H, Noguchi T, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Clinical Trial.
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy following 12 months of DAPT (aspirin group) after PCI for 5 years. ...CONCLUSIONS: Clopidogrel might be an attractive alternative to …
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy …
Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease.
Lo ST, Walker AL, Georges CJ, Li RH, Stern JA. Lo ST, et al. J Feline Med Surg. 2022 Apr;24(4):277-283. doi: 10.1177/1098612X211013736. Epub 2021 May 10. J Feline Med Surg. 2022. PMID: 33966532 Free PMC article.
METHODS: The study included 32 cats prescribed clopidogrel (18.75 mg PO q24h) and rivaroxaban (2.5 mg PO q24h) on an outpatient basis over a 5-year period. ...CONCLUSIONS AND RELEVANCE: Dual antithrombotic therapy with clopidogrel and rivaroxaban resulted in a low r …
METHODS: The study included 32 cats prescribed clopidogrel (18.75 mg PO q24h) and rivaroxaban (2.5 mg PO q24h) on an outpatient basis …
Biodegradation of clopidogrel bisulfate by Pseudomonas aeruginosa and Pseudomonas putida strains isolated from Algerian wastewater.
Fedeila M, Hachaïchi-Sadouk Z, Bautista LF, Simarro R. Fedeila M, et al. J Contam Hydrol. 2023 May;256:104198. doi: 10.1016/j.jconhyd.2023.104198. Epub 2023 May 4. J Contam Hydrol. 2023. PMID: 37167785
The clopidogrel bisulfate was degraded under aerobic conditions by two bacterial strains isolated from industrial effluents in El-Harrach, Algeria. ...This study reports, for the first time, the viability of the aerobic biodegradation of clopidogrel bisulf …
The clopidogrel bisulfate was degraded under aerobic conditions by two bacterial strains isolated from industrial effluents in …
Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube.
Aoki M, Naya M, Arima S, Shinohara K, Kato M, Shibuya K, Ohtawa M, Nagamitsu T, Otori K. Aoki M, et al. J Pharm Health Care Sci. 2021 May 4;7(1):18. doi: 10.1186/s40780-021-00202-1. J Pharm Health Care Sci. 2021. PMID: 33941283 Free PMC article.
The suspension of clopidogrel bisulfate tablet alone and the mixed suspension of clopidogrel bisulfate tablet and MgO tablet were passed through a feeding tube. ...In the tube passage test, the yield of clopidogrel (molecular form) from the mixt …
The suspension of clopidogrel bisulfate tablet alone and the mixed suspension of clopidogrel bisulfate tablet an …
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.
Premature discontinuation of the study drug occurred in 238 (47%) of 502 ticagrelor group patients randomly assigned to ticagrelor, and in 112 (22%) of 500 patients randomly assigned to clopidogrel. Primary bleeding outcome was significantly lower in the clopidogrel …
Premature discontinuation of the study drug occurred in 238 (47%) of 502 ticagrelor group patients randomly assigned to ticagrelor, and in 1 …
Pleiotropic effects of clopidogrel.
Kuszynski DS, Lauver DA. Kuszynski DS, et al. Purinergic Signal. 2022 Sep;18(3):253-265. doi: 10.1007/s11302-022-09876-0. Epub 2022 Jun 9. Purinergic Signal. 2022. PMID: 35678974 Free PMC article. Review.
Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y(12) receptor on platelets. ...In this review, we summarize both the P2Y(12) receptor-mediated and non-P2Y(12) receptor-mediated effects of clopidogrel …
Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y(12) receptor on p …
17,263 results
You have reached the last available page of results. Please see the User Guide for more information.